Back to Search
Start Over
Metformin-associated risk of acute dialysis in patients with type 2 diabetes: A nationwide cohort study.
- Source :
-
Diabetes, Obesity & Metabolism . Dec2016, Vol. 18 Issue 12, p1283-1287. 5p. - Publication Year :
- 2016
-
Abstract
- Recent guidelines governing anti-diabetic medications increasingly advocate metformin as first-line therapy in all patients with type 2 diabetes. However, metformin could be associated with increased risk of acute kidney injury ( AKI), acute dialysis and lactate acidosis in marginal patients. In a retrospective nationwide cohort study, a total of 168 443 drug-naïve patients with type 2 diabetes ≥50 years, initiating treatment with either metformin or sulphonyl in Denmark between 2000 and 2012 were included in this study (70.7% initiated treatment with metformin); calculation of 1-year risk of acute dialysis was based on g-standardization of cause-specific Cox regression models for acute dialysis, end-stage renal disease and death. One-year risks of acute dialysis were 92.4 per 100 000 (95% CI, 67.1-121.3) and 142.7 per 100 000 (95% CI, 118.3-168.0) for sulphonylurea and metformin, respectively. The metformin-associated 1-year risk of acute dialysis was increased by 50.3 per 100 000 (95% CI, 7.9-88.6), corresponding to a risk ratio of 1.53 (95% CI, 1.06-2.23), and a number needed to harm of 1988, thus providing evidence of potential concerns pertaining to the increasing use of metformin. [ABSTRACT FROM AUTHOR]
- Subjects :
- *METFORMIN
*TYPE 2 diabetes
*HEMODIALYSIS
*HYPOGLYCEMIC agents
*DIABETES
Subjects
Details
- Language :
- English
- ISSN :
- 14628902
- Volume :
- 18
- Issue :
- 12
- Database :
- Academic Search Index
- Journal :
- Diabetes, Obesity & Metabolism
- Publication Type :
- Academic Journal
- Accession number :
- 119458263
- Full Text :
- https://doi.org/10.1111/dom.12764